Meeting
2014 ASCO Annual Meeting
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
Authors
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center, Houston, TX
Hagop M. Kantarjian , Dong-Wook Kim , Javier Pinilla-Ibarz , Philipp D. Le Coutre , Ronald Paquette , Charles Chuah , Franck E. Nicolini , Jane Apperley , Hanna Jean Khoury , Moshe Talpaz , John F DiPersio , Michele Baccarani , Stephanie Lustgarten , Frank G. Haluska , Francois Guilhot , Michael W.N. Deininger , Andreas Hochhaus , Timothy P. Hughes , Neil P. Shah , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7081)
DOI
10.1200/jco.2014.32.15_suppl.7081
Abstract #
7081
Poster Bd #
366
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
First Author: Ronald J. Rieder
Poster
2011 ASCO Annual Meeting
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy.
First Author: S. B. Patel
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon